Compare Illumina, Inc. (ILMN) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Snowflake Inc — how do they compare? Illumina, Inc. trades at $193.42 (market cap $29.12B), while Snowflake Inc trades at $337.21 (market cap $116.01B). The key difference: Snowflake Inc is far larger — about 4× Illumina, Inc.'s market cap, and Snowflake Inc is trading nearer its 52-week high, Illumina, Inc. nearer its low. Which is the better fit depends on your goals.
| ILMN | SNOW | |
|---|---|---|
Market Cap | $29.12B | $116.01B |
Sector | Health | Technology |
52-Week High | $205.10 | $334.70 |
52-Week Low | $91.00 | $121.11 |
Enterprise Value | $30.48B | $115.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Snowflake (SNOW) trades at $334.7, up 1.27% on the day, reflecting strong momentum amid a bullish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.39 exceeding expectations. Revenue growth remains robust, reaching $3.63 billion in 2025, though profitability challenges persist with a net income margin of -23.79%. Recent news highlights product innovations, including AI integrations and security enhancements, driving investor optimism.
Outlook is supported by Wall Street's bullish consensus, with 81% of analysts rating SNOW a buy and a price target of $302.18. However, high valuation multiples, intense competition, and ongoing losses present significant risks. The stock's proximity to its 52-week high suggests limited near-term upside without further positive catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
